| Daniel Stuart Hagg, MD | |
|
2500 Ne Neff Rd, Bend, OR 97701-6015 | |
| (541) 706-2651 | |
| (541) 706-3765 |
| Full Name | Daniel Stuart Hagg |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 24 Years |
| Location | 2500 Ne Neff Rd, Bend, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710084587 | NPI | - | NPPES |
| 213475 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | MD24148 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Charles Medical Center - Bend | Bend, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Charles Health System Inc | 3870402852 | 150 |
News Archive
Initial results from a pilot study conducted by HMRI researchers based at the University of Newcastle suggest that there is an unmet treatment need for people suffering from depression and co-existing drug and alcohol problems.
Male mice have much greater brain distress in the week following a traumatic brain injury (TBI) than female mice, including skyrocketing inflammation and nerve cell death, say researchers at Georgetown University Medical Center.
Scientists of South Ural State University are studying enzymes that can break down stress hormones. They are also finding a way to regulate the activity of these enzymes. It will help to cure diseases caused by stress.
Centric Health Corporation, Canada's leading diversified healthcare company, announced today that it has entered into an agreement to acquire, amongst other things, all of the common units of LifeMark Health Limited Partnership.
Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.
› Verified 4 days ago
| Entity Name | St Charles Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982621447 PECOS PAC ID: 3870402852 Enrollment ID: O20040112000045 |
News Archive
Initial results from a pilot study conducted by HMRI researchers based at the University of Newcastle suggest that there is an unmet treatment need for people suffering from depression and co-existing drug and alcohol problems.
Male mice have much greater brain distress in the week following a traumatic brain injury (TBI) than female mice, including skyrocketing inflammation and nerve cell death, say researchers at Georgetown University Medical Center.
Scientists of South Ural State University are studying enzymes that can break down stress hormones. They are also finding a way to regulate the activity of these enzymes. It will help to cure diseases caused by stress.
Centric Health Corporation, Canada's leading diversified healthcare company, announced today that it has entered into an agreement to acquire, amongst other things, all of the common units of LifeMark Health Limited Partnership.
Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.
› Verified 4 days ago
| Entity Name | St Charles Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023331303 PECOS PAC ID: 8729111513 Enrollment ID: O20100730000227 |
News Archive
Initial results from a pilot study conducted by HMRI researchers based at the University of Newcastle suggest that there is an unmet treatment need for people suffering from depression and co-existing drug and alcohol problems.
Male mice have much greater brain distress in the week following a traumatic brain injury (TBI) than female mice, including skyrocketing inflammation and nerve cell death, say researchers at Georgetown University Medical Center.
Scientists of South Ural State University are studying enzymes that can break down stress hormones. They are also finding a way to regulate the activity of these enzymes. It will help to cure diseases caused by stress.
Centric Health Corporation, Canada's leading diversified healthcare company, announced today that it has entered into an agreement to acquire, amongst other things, all of the common units of LifeMark Health Limited Partnership.
Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Stuart Hagg, MD 3181 Sw Sam Jackson Park Rd, Uhn-67, Portland, OR 97239-3011 Ph: (503) 494-6668 | Daniel Stuart Hagg, MD 2500 Ne Neff Rd, Bend, OR 97701-6015 Ph: (541) 706-2651 |
News Archive
Initial results from a pilot study conducted by HMRI researchers based at the University of Newcastle suggest that there is an unmet treatment need for people suffering from depression and co-existing drug and alcohol problems.
Male mice have much greater brain distress in the week following a traumatic brain injury (TBI) than female mice, including skyrocketing inflammation and nerve cell death, say researchers at Georgetown University Medical Center.
Scientists of South Ural State University are studying enzymes that can break down stress hormones. They are also finding a way to regulate the activity of these enzymes. It will help to cure diseases caused by stress.
Centric Health Corporation, Canada's leading diversified healthcare company, announced today that it has entered into an agreement to acquire, amongst other things, all of the common units of LifeMark Health Limited Partnership.
Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.
› Verified 4 days ago
Alanna Mozena, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 Ne Neff Rd, Bend, OR 97701 Phone: 541-706-6892 Fax: 541-706-6813 | |
Ashley Marie Twyman, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 Ne Neff Rd, Bend, OR 97701 Phone: 541-706-6892 Fax: 541-706-6813 | |
Dr. Gilbert B. Lee, M.D. Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 1558 Sw Nancy Way, Bend, OR 97702 Phone: 541-312-8679 | |
Ms. Christine Marie Pierson, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 2965 Ne Conners Ave, Ste 280, Bend, OR 97701 Phone: 541-323-4269 | |
Dr. Michael N Harris, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1501 Ne Medical Center Dr, Bend, OR 97701 Phone: 541-382-2811 | |
Gordon Jeremy Juriansz, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 Ne Neff Rd, Bend, OR 97701 Phone: 541-706-6892 | |
Dr. Ronald Daniel Rosen, M.D. Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 918 Ne 5th St, Bend, OR 97701 Phone: 541-388-3804 Fax: 541-388-3856 |